Medicines for Malaria Venture (MMV)

Startseite
Schweiz
Geneva
Medicines for Malaria Venture (MMV)

A leading PDP working to reduce the burden of malaria in disease-endemic countries.

04/03/2026

When it comes to prevention, three powerful tools are helping countries protect more people and save more lives.

The World Health Organization’s latest biennial report for Burkina Faso reflects progress in the country’s malaria control and elimination efforts, including the scale-up of a trio of prevention tools: bed nets, chemoprevention and vaccines.

The 2024–2025 period saw the distribution of 15 million insecticide-treated bed nets, seasonal chemoprevention campaigns reaching more than 5 million children, and the scale-up of malaria vaccines across 70 health districts.

As one of the countries bearing a significant share of the global malaria burden, Burkina Faso’s progress highlights how strengthened health systems and expanded access to essential services can sustain gains despite security constraints, population displacement and climate-related pressures.

Read the report: bit.ly/4rN5JKf

03/03/2026

Leadership matters most when research needs to translate into action.

As a long-time MMV partner, Marcus Lacerda has helped generate country-led evidence needed to adopt new tools for vivax in Brazil and beyond.

Now, Marcus is bringing this experience to his new role as Director of WHO TDR, where he'll help advance the organization’s strategy of building locally driven research to address global health challenges.

MMV looks forward to continuing our partnership with Marcus and TDR, turning research into real-world impact for the patients at the heart of our work.

28/02/2026

In case you missed it: new evidence on the value of investing in malaria through MMV.

Last week, a study published in The Lancet Global Health revealed that investments in MMV between 2000 and 2023 generated 13 times their value in health benefits, with each dollar delivering a 52% return per year, every year.

The takeaway is simple: support for R&D and access pays off – for patients, health systems and economies.

Read the study for more insights into the long-term impact of MMV's work: bit.ly/4r59Ikm

27/02/2026

When researchers gain access to new collaborations and expertise, the impact goes far beyond a single project.

In a recent discussion with MMV, Dr Peter Cheuka from the University of Zambia shares how his collaboration through our African call for proposals has facilitated knowledge exchange and moved his team closer to identifying novel molecules to optimize interventions.

Read the interview, and don’t forget that MMV’s latest Call for proposals ends today at midnight: bit.ly/3MRp1ik

26/02/2026

This week, the SMC Alliance and the Alliance for Malaria Prevention are holding their first-ever joint annual meeting in Kampala, Uganda. National malaria programmes and partners, including MMV, have come together to share lessons learned and innovations, and help shape the next phase of prevention through preventive medicines and insecticide-treated nets (ITNs).

The World Health Organization recommended seasonal malaria chemoprevention in 2012 for children under five, and since then, the SMC Alliance has helped accelerate the scale-up of these preventive medicines, which now protect an average of 54 million children in 20 countries each year.

Similarly, the Alliance for Malaria Prevention has worked for more than two decades to expand access to ITNs in endemic countries. Bringing these two networks together highlights how combining proven prevention tools can help countries protect more people and reduce disease burden.

25/02/2026

Marine sponges could hold the starting points for next-generation antimalarials.

As a grantee through MMV’s African call for proposals, Dr Godwin Akpeko Dziwornu is exploring compounds derived from marine sponges to inform drug discovery.

In an interview with MMV, he reflects on the challenges of recreating these complex natural molecules in the lab, and how the project has enabled an efficient way to produce one of them for further research.

Read the interview. And don’t forget that MMV’s latest Call for proposals ends this Friday: bit.ly/3MPfsk2

23/02/2026

Last call to submit your proposals!

MMV’s 23rd Call for proposals ends this Friday, 27 February.

Help us shape the next generation of interventions. We’re looking for compounds addressing key prevention, treatment and elimination needs, including innovative biology beyond small molecules.

Guidelines and submission info 👉 bit.ly/3XFUG8n

19/02/2026

How will climate change impact malaria elimination efforts?

A new study drawing on 25 years of African data projects up to 123 million additional malaria cases and more than 500,000 additional deaths by 2050 due to climate change.

Most of that increase is expected in places where already exists, driven largely by extreme weather disrupting health systems and control efforts. The findings point to the need for climate-resilient malaria programmes, including adaptable medicines and tools.

This is a key focus of MMV and partners, as we work to develop and deliver next-generation antimalarials that are longer-lasting, easier to use and designed to stay ahead of resistance.

Learn more about how could impact malaria elimination, and what future tools and strategies must do to keep pace: bit.ly/4rO8o5U

18/02/2026

Malaria control is entering a new phase, where stronger country-led efforts will be central to protecting more people.

After decades of progress against , shifting funding, antimalarial drug resistance and evolving parasites are changing the risk landscape. A new report published by United to Beat Malaria and Malaria No More explores how countries and partners can manage this transition.

Read it to see how data-driven planning, sustainable financing and partnerships can support long-term, country-led responses 👉 bit.ly/4rgP6GJ

17/02/2026

A new analysis in The Lancet Global Health finds that, between 2000 and 2023, investments in MMV generated 13 times their value in health benefits. What’s more, each dollar invested delivers a 52% return per year, every year.

The findings show how long-term support for malaria R&D leads to major gains for patients, health systems and economies.

Learn more about the study and why product development partnerships like MMV offer a proven model for turning global health investment into measurable results: bit.ly/4aC2yhh

14/02/2026

Malaria remains a global challenge, even for countries that have eliminated it.

A new article from the Institute for Research in Biomedicine in Switzerland examines how local transmission has been reported in recent years in places that had previously eliminated , and how climate change and global mobility may reshape risk over time.

The message is an important one: progress against the disease depends on sustained vigilance and continued investment in and elimination efforts.

Read why advancing malaria elimination in endemic areas also strengthens global health security and benefits us all: bit.ly/4bkEUYx

13/02/2026

AI’s role in control and elimination goes beyond drug discovery.

New efforts in countries like Rwanda are exploring how AI tools can improve diagnosis and better anticipate when and where malaria cases are likely to occur, supporting decision-making closer to the community level.

As interest in AI grows, this highlights a broader shift towards using data-driven tools not only to develop new interventions, but to inform decisions in real-world settings.

Read about this and other AI applications with the potential to overcome healthcare challenges in Africa: bit.ly/4bptDpP

Adresse

20, Route De Pré-Bois
Geneva
1215

Telefon

+41 22 555 03 00

Webseite

http://www.mmv.org/

Benachrichtigungen

Lassen Sie sich von uns eine E-Mail senden und seien Sie der erste der Neuigkeiten und Aktionen von Medicines for Malaria Venture (MMV) erfährt. Ihre E-Mail-Adresse wird nicht für andere Zwecke verwendet und Sie können sich jederzeit abmelden.

Verknüpfungen

Wollen Sie Ihr Praxis zum Top-Klinik in Geneva machen?